Moderna cut to sell from neutral by Rothschild & Co
Rothschild & Co downgraded Moderna to sell from neutral and raised its price target to $81.00 a share from $40.00.
Rothschild & Co raised its price target on Moderna to $81.00 a share from $40.00 and kept the rating at sell, according to Benzinga ratings actions.